| Name | Title | Contact Details |
|---|---|---|
Patrick Baumhof |
Senior Vice President of Technology | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
Mariola Fotin-Mleczek |
Chief Technology Officer | Profile |
Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.
BTI Products is a Bayfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
Genosco is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Quad Five Materials Bio is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.